FDA Inspection 1035076 — Max Sung
The FDA completed an inspection of Max Sung on Nov 2, 2017 in New York, NY. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Nov 2, 2017
- Fiscal Year
- 2018
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- New York, NY (United States)
Additional Details
Clinical Investigator (CI)